Literature DB >> 27112120

Cognitive variability in bipolar II disorder: who is cognitively impaired and who is preserved.

Brisa Solé1, Esther Jiménez1, Carla Torrent1, Caterina Del Mar Bonnin1, Imma Torres1, María Reinares1, Ángel Priego2, Manel Salamero3, Francesc Colom1, Cristina Varo1, Eduard Vieta1, Anabel Martínez-Arán1.   

Abstract

OBJECTIVES: Although it is well established that euthymic patients with bipolar disorder can have cognitive impairment, substantial heterogeneity exists and little is known about the extent and severity of impairment within the bipolar II disorder subtype. Therefore, the main aim of this study was to analyze cognitive variability in a sample of patients with bipolar II disorder.
METHODS: The neuropsychological performance of 116 subjects, including 64 euthymic patients with bipolar II disorder and 52 healthy control subjects, was examined and compared by means of a comprehensive neurocognitive battery. Neurocognitive data were analyzed using a cluster analysis to examine whether there were specific groups based on neurocognitive patterns. Subsequently, subjects from each cluster were compared on demographic, clinical, and functional variables.
RESULTS: A three-cluster solution was identified with an intact neurocognitive group (n = 29, 48.3%), an intermediate or selectively impaired group (n = 24, 40.0%), and a globally impaired group (n = 7, 11.6%). Among the three clusters, statistically significant differences were observed in premorbid intelligence quotient (p = 0.002), global functional outcome (p = 0.021), and leisure activities (p = 0.001), with patients in the globally impaired cluster showing the lowest attainments. No differences in other clinical characteristics were found among the groups.
CONCLUSIONS: These results confirm that neurocognitive variability is also present among patients with bipolar II disorder. Approximately one-half of the patients with bipolar II disorder were cognitively impaired, and among them 12% were severely and globally impaired. The identification of different cognitive profiles may help to develop cognitive remediation programs specifically tailored for each cognitive profile.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bipolar II disorder; cluster analysis; neurocognition

Mesh:

Year:  2016        PMID: 27112120     DOI: 10.1111/bdi.12385

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  13 in total

1.  Modifiable and non-modifiable factors associated with functional impairment during the inter-episodic periods of bipolar disorder.

Authors:  Andrea Murru; Isabella Pacchiarotti; Norma Verdolini; Maria Reinares; Carla Torrent; Pierre-Alexis Geoffroy; Frank Bellivier; Pierre-Michel Llorca; Eduard Vieta; Ludovic Samalin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-05-22       Impact factor: 5.270

Review 2.  Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment.

Authors:  Ni Xu; Benjamin Huggon; Kate E A Saunders
Journal:  CNS Drugs       Date:  2020-01       Impact factor: 5.749

3.  Neurocognitive subtypes in patients with bipolar disorder and their unaffected siblings.

Authors:  M Russo; T E Van Rheenen; M Shanahan; K Mahon; M M Perez-Rodriguez; A Cuesta-Diaz; E Larsen; A K Malhotra; K E Burdick
Journal:  Psychol Med       Date:  2017-06-07       Impact factor: 7.723

4.  The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management.

Authors:  Roger S McIntyre; Martin Alda; Ross J Baldessarini; Michael Bauer; Michael Berk; Christoph U Correll; Andrea Fagiolini; Kostas Fountoulakis; Mark A Frye; Heinz Grunze; Lars V Kessing; David J Miklowitz; Gordon Parker; Robert M Post; Alan C Swann; Trisha Suppes; Eduard Vieta; Allan Young; Mario Maj
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

5.  Polygenic Risk Scores Differentiating Schizophrenia From Bipolar Disorder Are Associated With Premorbid Intelligence in Schizophrenia Patients and Healthy Subjects.

Authors:  Kazutaka Ohi; Daisuke Nishizawa; Shunsuke Sugiyama; Kentaro Takai; Ayumi Kuramitsu; Junko Hasegawa; Midori Soda; Kiyoyuki Kitaichi; Ryota Hashimoto; Kazutaka Ikeda; Toshiki Shioiri
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

Review 6.  Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies.

Authors:  Brisa Solé; Esther Jiménez; Carla Torrent; Maria Reinares; Caterina Del Mar Bonnin; Imma Torres; Cristina Varo; Iria Grande; Elia Valls; Estela Salagre; Jose Sanchez-Moreno; Anabel Martinez-Aran; André F Carvalho; Eduard Vieta
Journal:  Int J Neuropsychopharmacol       Date:  2017-08-01       Impact factor: 5.176

7.  The correlation between longitudinal changes in hypothalamic-pituitary-adrenal (HPA)-axis activity and changes in neurocognitive function in mixed-state bipolar II disorder.

Authors:  Hsuan-Han Lee; Cheng-Ho Chang; Liang-Jen Wang; Chih-Ching Wu; Hsing-Ling Chen; Ti Lu; Ru-Band Lu; Sheng-Yu Lee
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-15       Impact factor: 2.570

Review 8.  Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force.

Authors:  Ralph Kupka; Anne Duffy; Jan Scott; Jorge Almeida; Vicent Balanzá-Martínez; Boris Birmaher; David J Bond; Elisa Brietzke; Ines Chendo; Benicio N Frey; Iria Grande; Danella Hafeman; Tomas Hajek; Manon Hillegers; Marcia Kauer-Sant'Anna; Rodrigo B Mansur; Afra van der Markt; Robert Post; Mauricio Tohen; Hailey Tremain; Gustavo Vazquez; Eduard Vieta; Lakshmi N Yatham; Michael Berk; Martin Alda; Flávio Kapczinski
Journal:  Bipolar Disord       Date:  2021-07-23       Impact factor: 5.345

9.  Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Authors:  K W Miskowiak; K E Burdick; A Martinez-Aran; C M Bonnin; C R Bowie; A F Carvalho; P Gallagher; B Lafer; C López-Jaramillo; T Sumiyoshi; R S McIntyre; A Schaffer; R J Porter; I J Torres; L N Yatham; A H Young; L V Kessing; E Vieta
Journal:  Bipolar Disord       Date:  2017-09-12       Impact factor: 6.744

10.  Does Cognitive Dysfunction in Bipolar Disorder Qualify as a Diagnostic Intermediate Phenotype?-A Perspective Paper.

Authors:  Lars Vedel Kessing; Kamilla Miskowiak
Journal:  Front Psychiatry       Date:  2018-10-08       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.